Hematological Neoplasms

On March 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

Yescarta (Axicabtagene Ciloleucel), a revolutionary CAR-T cell therapy, has garnered significant attention since its FDA approval in 2017. This article aims to provide a comprehensive overview of Yescarta, including its FDA approval history, indications, efficacy, safety profile, and potential future developments.

Yescarta, also known as Axicabtagene Ciloleucel (Axi-Cel) or 奕凯达 (阿基伦塞) in Chinese, is a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen.

Yescarta (Axicabtagene ciloleucel, Axi-cel) has revolutionized the treatment landscape for lymphoma since its initial approval by the US FDA on October 18, 2017. As the world’s first chimeric antigen receptor T-cell (CAR-T) therapy for adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have received two or more lines of systemic therapy, Yescarta has ushered in a new era in lymphoma treatment.

In the realm of oncology, the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) has witnessed significant advancements over the past decade.

The ZUMA-7 trial, a randomized, open-label, multicenter Phase III study, represents a pivotal moment in the Yescarta narrative.

One such therapy is Yescarta (axicabtagene ciloleucel), a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy that specifically targets the CD19 antigen.

Yescarta, also known as axicabtagene ciloleucel, is a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy that has been hailed as a significant breakthrough in the treatment of certain types of lymphoma.